PL3010513T3 - Skojarzenie RO5503781 i kapecytabiny do leczenia raka - Google Patents

Skojarzenie RO5503781 i kapecytabiny do leczenia raka

Info

Publication number
PL3010513T3
PL3010513T3 PL14732136T PL14732136T PL3010513T3 PL 3010513 T3 PL3010513 T3 PL 3010513T3 PL 14732136 T PL14732136 T PL 14732136T PL 14732136 T PL14732136 T PL 14732136T PL 3010513 T3 PL3010513 T3 PL 3010513T3
Authority
PL
Poland
Prior art keywords
capecitabine
combination
cancer therapy
cancer
therapy
Prior art date
Application number
PL14732136T
Other languages
English (en)
Inventor
Brian Higgins
Gwen Nichols
Kathryn E Packman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL3010513T3 publication Critical patent/PL3010513T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14732136T 2013-06-19 2014-06-16 Skojarzenie RO5503781 i kapecytabiny do leczenia raka PL3010513T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361836894P 2013-06-19 2013-06-19
EP14732136.8A EP3010513B1 (en) 2013-06-19 2014-06-16 Combination of ro5503781 and capecitabine for cancer therapy
PCT/EP2014/062490 WO2014202492A1 (en) 2013-06-19 2014-06-16 Combination of ro5503781 and capecitabine for cancer therapy

Publications (1)

Publication Number Publication Date
PL3010513T3 true PL3010513T3 (pl) 2019-11-29

Family

ID=50981495

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14732136T PL3010513T3 (pl) 2013-06-19 2014-06-16 Skojarzenie RO5503781 i kapecytabiny do leczenia raka

Country Status (14)

Country Link
US (1) US20160129033A1 (pl)
EP (1) EP3010513B1 (pl)
JP (1) JP6239745B2 (pl)
KR (1) KR20160007662A (pl)
CN (1) CN105307660A (pl)
BR (1) BR112015029658A2 (pl)
CA (1) CA2912816A1 (pl)
ES (1) ES2741003T3 (pl)
HK (1) HK1214502A1 (pl)
MX (1) MX2015016893A (pl)
PL (1) PL3010513T3 (pl)
RU (1) RU2015152577A (pl)
TR (1) TR201910701T4 (pl)
WO (1) WO2014202492A1 (pl)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227932A1 (en) * 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US8232298B2 (en) * 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
ES2431564T3 (es) * 2006-03-22 2013-11-27 Janssen Pharmaceutica N.V. Inhibidores de la interacción entre MDM2 y p53
WO2008034039A2 (en) * 2006-09-15 2008-03-20 Nexuspharma Inc. Novel tetrahydro-isoquinolines
JP5053674B2 (ja) * 2007-03-26 2012-10-17 テルモ株式会社 耳式体温計
AU2009279771B2 (en) * 2008-08-04 2015-05-14 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
HK1214502A1 (zh) 2016-07-29
TR201910701T4 (tr) 2019-08-21
BR112015029658A2 (pt) 2017-07-25
WO2014202492A1 (en) 2014-12-24
US20160129033A1 (en) 2016-05-12
CA2912816A1 (en) 2014-12-24
RU2015152577A (ru) 2017-07-24
ES2741003T3 (es) 2020-02-07
JP2016522228A (ja) 2016-07-28
CN105307660A (zh) 2016-02-03
MX2015016893A (es) 2016-04-07
EP3010513B1 (en) 2019-06-05
JP6239745B2 (ja) 2017-11-29
KR20160007662A (ko) 2016-01-20
EP3010513A1 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
LT3033086T (lt) Kombinuota terapija vėžiui gydyti
GB201322725D0 (en) Cancer therapy
SG10201801965RA (en) Treatment of cancer with dihydropyrazino-pyrazines
HK1220900A1 (zh) 癌症的治療
ZA201507733B (en) Treatment of cancer with dihydropyrazino-pyrazines
HK1213817A1 (zh) 治療癌症的方法
GB201308325D0 (en) Cancer Therapy
HK1219513A1 (zh) 治療癌症的方法
EP2961412A4 (en) CANCER THERAPY
GB201403083D0 (en) Treatment of cancer
HK1213475A1 (zh) 用於癌症治療的 、卡培他濱和奧沙利鉑的組合
HK1232118A1 (zh) 癌症的治療
HK1214502A1 (zh) 用於癌症治療的 和卡培他濱的組合
TWI561255B (en) Use of umirolimus and its derivatives for treating cancer
GB201322346D0 (en) Combination treatment of cancer
GB201317373D0 (en) Treatment and prevention of cancer
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201308529D0 (en) Treatment of cancer
GB201305020D0 (en) Treatment of cancer
GB201301685D0 (en) Diagnosis and treatment of cancer
GB201317213D0 (en) Cancer Therapy
GB201303115D0 (en) Detection and treatment of liver cancer